John Rhoden, Ph.D.Director, Preclinical Development at Fusion Pharmaceuticals
Dr. John Rhoden is the Senior Director of Nonclinical Development at Fusion Pharmaceuticals in Boston, MA. He oversees nonclinical development activities, including PK/PD, toxicology, and bioanalysis, supporting Fusion’s pipeline of proprietary and partnered targeted alpha therapeutics. Prior to Fusion. Dr. Rhoden worked in several roles in ADME/PK/PD and translational sciences at Eli Lilly and Company supporting biologics programs in oncology and immunology. He is a proponent of applying quantitative tools and fit-for-purpose modeling to guide experimentation and decision making in complex situations.
Dr. Rhoden received his Ph.D. chemical engineering from the Massachusetts Institute of Technology and a B.S. in chemical engineering from North Carolina State University.